Doctors in the UK have just announced that for the first time in the country, the main drug that has been used in treating malaria amongst their patients has failed.
Four patients who had gotten the disease whilst traveling in Africa were admitted to the hospital upon their return.
Reports state that when they were treated the first time around, it had been a success. However, just one month later they had been hospitalized again as symptoms of the infection surfaced yet again.
Experts on the matter have stated that this case can prove to be a potentially dangerous matter for the future as this form of malaria may possible by resistant to their most successful treatment.
Even Deadlier Than It Was
Experts from London’s School of Hygiene as well as Tropical Medicine have studied this case more thoroughly by examining the blood samples of all the infected patients.
Two of the infected patients had been on a trip to Uganda, one from Angola, and the last one from Liberia.
According to the experts analyzing this matter, they state that their key drug in treating malaria failed here because strains of the infection had showed signs of decreased vulnerability towards their combination of the drug artemether-lumefantrine or AL.
Ok for Now
However all patients were then treated through alternative methods that eventually prevented their infection from spreading even further into a fatal state.
The man who led the case study, Dr. Colin Sutherland states that their initial drug combination may need to undergo further examination for additional use in future cases.
“Fortunately there are other effective drugs available,” Dr. Sutherland remarked.
The doctor added that other frontline doctors should be on high alert for drugs that contain artemisinin that may very well prove to be unsuccessful for them later.
Dr. Sutherland then urged for a detailed database concerning the results of the AL drug regarding those infected with malaria within the UK to be created.
This strategy he says will prove to be of great assistance for them in determining whether or not their key drug for treating the disease poses any threats.